Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DNLI |
---|---|---|
09:32 ET | 7553 | 21.805 |
09:34 ET | 1550 | 21.67 |
09:36 ET | 274 | 21.735 |
09:38 ET | 600 | 21.705 |
09:39 ET | 100 | 21.66 |
09:41 ET | 2519 | 21.69 |
09:45 ET | 749 | 21.6 |
09:48 ET | 600 | 21.57 |
09:50 ET | 400 | 21.54 |
09:52 ET | 200 | 21.42 |
09:54 ET | 700 | 21.49 |
09:56 ET | 600 | 21.53 |
09:57 ET | 100 | 21.51 |
09:59 ET | 100 | 21.54 |
10:01 ET | 7148 | 21.39 |
10:03 ET | 5341 | 21.405 |
10:06 ET | 891 | 21.32 |
10:08 ET | 3690 | 21.36 |
10:10 ET | 700 | 21.25 |
10:12 ET | 1256 | 21.25 |
10:14 ET | 1486 | 21.225 |
10:15 ET | 1612 | 21.23 |
10:17 ET | 100 | 21.24 |
10:19 ET | 300 | 21.21 |
10:24 ET | 2958 | 21.24 |
10:26 ET | 300 | 21.24 |
10:28 ET | 1082 | 21.32 |
10:30 ET | 300 | 21.29 |
10:32 ET | 468 | 21.281 |
10:33 ET | 700 | 21.22 |
10:37 ET | 200 | 21.17 |
10:39 ET | 1192 | 21.1783 |
10:42 ET | 800 | 21.16 |
10:46 ET | 1100 | 21.15 |
10:48 ET | 2349 | 21.095 |
10:50 ET | 4333 | 21.08 |
10:51 ET | 400 | 21.06 |
10:53 ET | 600 | 21 |
10:55 ET | 4027 | 21.045 |
10:57 ET | 1229 | 21.03 |
11:00 ET | 400 | 21.02 |
11:02 ET | 1976 | 21.07 |
11:04 ET | 300 | 21.08 |
11:06 ET | 200 | 21.06 |
11:08 ET | 800 | 21.045 |
11:09 ET | 10467 | 21.055 |
11:11 ET | 7866 | 20.98 |
11:13 ET | 14030 | 21.02 |
11:15 ET | 1587 | 20.9 |
11:18 ET | 2918 | 20.89 |
11:20 ET | 13173 | 20.855 |
11:22 ET | 14507 | 20.79 |
11:24 ET | 3400 | 20.835 |
11:26 ET | 2365 | 20.8 |
11:27 ET | 1083 | 20.81 |
11:29 ET | 1200 | 20.8 |
11:31 ET | 600 | 20.83 |
11:33 ET | 3507 | 20.905 |
11:36 ET | 500 | 20.845 |
11:38 ET | 1200 | 20.83 |
11:40 ET | 2600 | 20.79 |
11:42 ET | 1400 | 20.775 |
11:44 ET | 7741 | 20.76 |
11:45 ET | 3400 | 20.765 |
11:47 ET | 1600 | 20.62 |
11:49 ET | 1090 | 20.59 |
11:51 ET | 4006 | 20.6 |
11:54 ET | 3783 | 20.7231 |
11:56 ET | 100 | 20.69 |
11:58 ET | 1654 | 20.645 |
12:00 ET | 1000 | 20.66 |
12:02 ET | 1200 | 20.655 |
12:03 ET | 1000 | 20.66 |
12:05 ET | 2164 | 20.7 |
12:07 ET | 2800 | 20.755 |
12:09 ET | 2378 | 20.71 |
12:12 ET | 800 | 20.72 |
12:14 ET | 1002 | 20.725 |
12:16 ET | 300 | 20.73 |
12:18 ET | 500 | 20.695 |
12:20 ET | 1550 | 20.6723 |
12:21 ET | 2260 | 20.72 |
12:23 ET | 400 | 20.72 |
12:25 ET | 1536 | 20.69 |
12:27 ET | 1400 | 20.68 |
12:30 ET | 600 | 20.67 |
12:32 ET | 4198 | 20.615 |
12:34 ET | 100 | 20.59 |
12:36 ET | 22538 | 20.45 |
12:38 ET | 7241 | 20.52 |
12:39 ET | 600 | 20.59 |
12:41 ET | 400 | 20.59 |
12:43 ET | 1314 | 20.665 |
12:45 ET | 300 | 20.65 |
12:48 ET | 400 | 20.66 |
12:50 ET | 400 | 20.68 |
12:52 ET | 500 | 20.71 |
12:54 ET | 2020 | 20.675 |
12:56 ET | 900 | 20.71 |
12:57 ET | 231 | 20.67 |
12:59 ET | 900 | 20.725 |
01:01 ET | 775 | 20.755 |
01:03 ET | 1057 | 20.75 |
01:06 ET | 100 | 20.73 |
01:08 ET | 900 | 20.775 |
01:10 ET | 400 | 20.77 |
01:12 ET | 500 | 20.8 |
01:14 ET | 2640 | 20.76 |
01:15 ET | 2000 | 20.73 |
01:17 ET | 500 | 20.73 |
01:19 ET | 700 | 20.73 |
01:21 ET | 4736 | 20.765 |
01:24 ET | 11667 | 20.74 |
01:26 ET | 970 | 20.73 |
01:28 ET | 1056 | 20.745 |
01:30 ET | 900 | 20.78 |
01:32 ET | 1755 | 20.78 |
01:33 ET | 200 | 20.785 |
01:35 ET | 6847 | 20.77 |
01:37 ET | 9015 | 20.805 |
01:39 ET | 900 | 20.78 |
01:42 ET | 1300 | 20.74 |
01:44 ET | 900 | 20.7 |
01:46 ET | 600 | 20.725 |
01:48 ET | 1656 | 20.77 |
01:50 ET | 200 | 20.76 |
01:51 ET | 2113 | 20.72 |
01:53 ET | 2144 | 20.74 |
01:55 ET | 900 | 20.705 |
01:57 ET | 200 | 20.67 |
02:00 ET | 1143 | 20.66 |
02:02 ET | 714 | 20.68 |
02:04 ET | 500 | 20.7 |
02:06 ET | 1869 | 20.76 |
02:08 ET | 3611 | 20.79 |
02:09 ET | 1600 | 20.745 |
02:11 ET | 827 | 20.72 |
02:13 ET | 900 | 20.71 |
02:15 ET | 3242 | 20.73 |
02:18 ET | 400 | 20.73 |
02:20 ET | 2203 | 20.73 |
02:22 ET | 1053 | 20.72 |
02:24 ET | 1770 | 20.77 |
02:26 ET | 3873 | 20.7 |
02:27 ET | 2032 | 20.73 |
02:29 ET | 146 | 20.73 |
02:31 ET | 867 | 20.7191 |
02:33 ET | 700 | 20.725 |
02:36 ET | 1875 | 20.74 |
02:38 ET | 1925 | 20.715 |
02:40 ET | 1276 | 20.7 |
02:42 ET | 600 | 20.68 |
02:44 ET | 500 | 20.68 |
02:45 ET | 2352 | 20.71 |
02:47 ET | 832 | 20.705 |
02:49 ET | 899 | 20.72 |
02:51 ET | 1230 | 20.73 |
02:54 ET | 600 | 20.76 |
02:56 ET | 963 | 20.76 |
02:58 ET | 1154 | 20.805 |
03:00 ET | 3027 | 20.815 |
03:02 ET | 3047 | 20.765 |
03:03 ET | 1995 | 20.82 |
03:05 ET | 400 | 20.815 |
03:07 ET | 923 | 20.84 |
03:09 ET | 1200 | 20.825 |
03:12 ET | 1932 | 20.845 |
03:14 ET | 941 | 20.84 |
03:16 ET | 1986 | 20.85 |
03:18 ET | 2900 | 20.85 |
03:20 ET | 1325 | 20.86 |
03:21 ET | 2022 | 20.881 |
03:23 ET | 1643 | 20.9 |
03:25 ET | 6060 | 20.89 |
03:27 ET | 1215 | 20.885 |
03:30 ET | 1790 | 20.891 |
03:32 ET | 2640 | 20.92 |
03:34 ET | 5451 | 21.06 |
03:36 ET | 25835 | 21.055 |
03:38 ET | 3109 | 21.03 |
03:39 ET | 7389 | 21.005 |
03:41 ET | 6805 | 21.06 |
03:43 ET | 4352 | 21.01 |
03:45 ET | 4190 | 21.01 |
03:48 ET | 5598 | 21.03 |
03:50 ET | 5113 | 21.11 |
03:52 ET | 9506 | 21.02 |
03:54 ET | 9661 | 20.93 |
03:56 ET | 22322 | 20.79 |
03:57 ET | 31280 | 20.72 |
03:59 ET | 261253 | 20.73 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Denali Therapeutics Inc | 3.0B | -21.5x | --- |
MorphoSys AG | 2.7B | -5.4x | --- |
Amicus Therapeutics Inc | 3.0B | -20.6x | --- |
Genmab A/S | 17.4B | 22.0x | +22.71% |
Twist Bioscience Corp | 2.9B | -14.9x | --- |
Arrowhead Pharmaceuticals Inc | 3.2B | -6.1x | --- |
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
---|---|
Revenue (TTM) | $295.4M |
Shares Outstanding | 142.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.37 |
EPS | $-0.97 |
Book Value | $7.45 |
P/E Ratio | -21.5x |
Price/Sales (TTM) | 10.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -65.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.